Deerfield Management ("Deerfield") is an American investment firm headquartered in New York City. It is focused on making public and private investments in the healthcare and biotechnology industries. Deerfield is considered to be one of the largest dedicated healthcare investment firms in the world.

Deerfield was founded in 1994 by Arnold Snider with $17 million in equity. Snider was previously a pharmaceutical analyst for Kidder Peabody and then a managing director at Tiger Management making Deerfield one of the Tiger Cubs funds founded by former Tiger Management employees.

In 2000, James Flynn joined Deerfield and would later become CEO of the firm.

In 2005, Snider formally retired from Deerfield.

In 2015, Deerfield secured $550 million for its first healthcare innovations fund, aimed at scientific advancements that could lead to new therapeutics in genetic diseases, cancer and orphan diseases.

In February 2019, it was reported that Deerfield has been profitable for the last five years with four of them having double-digit gains. It had a return of 11% for 2018.

In May 2019, Deerfield acquired 345 Park Avenue South which would become its new headquarters.

In 2020, Deerfield raised $880 million for its second healthcare innovations fund, and in 2025 it raised $600 million for its third.